Pharma News

BI-685509 by Boehringer Ingelheim International for Systemic Sclerosis (Scleroderma): Likelihood of Approval

BI-685509 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis (Scleroderma) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BI-685509’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BI-685509 overview

BI-685509 is under development for the treatment of clinically significant portal hypertension, cirrhosis, diabetic nephropathy, adults with early progressive diffuse cutaneous systemic sclerosis and chronic kidney disease. It is administered orally as a tablet. It acts by targeting soluble guanylate cyclase (sGC).

Boehringer Ingelheim International overview

Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets of pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for Swine, Ruminant, Poultry, Horses, Pets etc. It operates facilities for manufacture pharmaceuticals and medical products. Boehringer is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.

For a complete picture of BI-685509’s drug-specific PTSR and LoA scores, buy the report here.

Source link
#BI685509 #Boehringer #Ingelheim #International #Systemic #Sclerosis #Scleroderma #Likelihood #Approval

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *